What's in ZymoGenetics's pipeline?

ZymoGenetics has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with ZymoGenetics's portfolio?

Top competitors by shared drug class: AryoGen Pharmed Co., Baxalta now part of Shire, Nicoletta C Machin, Novo Nordisk A/S.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zymogenetics.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

ZymoGenetics — Portfolio Competitive Intelligence Brief

ZymoGenetics pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
rThrombin	rThrombin	phase 3	Recombinant coagulation factor	Fibrinogen (Factor I)	Hematology

Therapeutic area mix

Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AryoGen Pharmed Co. · 1 shared drug class
Baxalta now part of Shire · 1 shared drug class
Nicoletta C Machin · 1 shared drug class
Novo Nordisk A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ZymoGenetics:

Cite this brief

Drug Landscape (2026). ZymoGenetics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zymogenetics. Accessed 2026-05-13.